ArticleBMC cancer2022

CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab.

Tomoyuki Matsunaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.